92 related articles for article (PubMed ID: 18394172)
1. Molecular analysis reveals heterogeneity of mouse mammary tumors conditionally mutant for Brca1.
Wright MH; Robles AI; Herschkowitz JI; Hollingshead MG; Anver MR; Perou CM; Varticovski L
Mol Cancer; 2008 Apr; 7():29. PubMed ID: 18394172
[TBL] [Abstract][Full Text] [Related]
2. Alpha-6 integrin deletion delays the formation of Brca1/p53-deficient basal-like breast tumors by restricting luminal progenitor cell expansion.
Faraldo MM; Romagnoli M; Wallon L; Dubus P; Deugnier MA; Fre S
Breast Cancer Res; 2024 Jun; 26(1):91. PubMed ID: 38835038
[TBL] [Abstract][Full Text] [Related]
3. GATA3 functions downstream of BRCA1 to suppress EMT in breast cancer.
Bai F; Zhang LH; Liu X; Wang C; Zheng C; Sun J; Li M; Zhu WG; Pei XH
Theranostics; 2021; 11(17):8218-8233. PubMed ID: 34373738
[No Abstract] [Full Text] [Related]
4. Identification and characterization of cancer initiating cells from BRCA1 related mammary tumors using markers for normal mammary stem cells.
Vassilopoulos A; Wang RH; Petrovas C; Ambrozak D; Koup R; Deng CX
Int J Biol Sci; 2008 May; 4(3):133-42. PubMed ID: 18461147
[TBL] [Abstract][Full Text] [Related]
5. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors.
Herschkowitz JI; Simin K; Weigman VJ; Mikaelian I; Usary J; Hu Z; Rasmussen KE; Jones LP; Assefnia S; Chandrasekharan S; Backlund MG; Yin Y; Khramtsov AI; Bastein R; Quackenbush J; Glazer RI; Brown PH; Green JE; Kopelovich L; Furth PA; Palazzo JP; Olopade OI; Bernard PS; Churchill GA; Van Dyke T; Perou CM
Genome Biol; 2007; 8(5):R76. PubMed ID: 17493263
[TBL] [Abstract][Full Text] [Related]
6. Biomarkers of residual disease, disseminated tumor cells, and metastases in the MMTV-PyMT breast cancer model.
Franci C; Zhou J; Jiang Z; Modrusan Z; Good Z; Jackson E; Kouros-Mehr H
PLoS One; 2013; 8(3):e58183. PubMed ID: 23520493
[TBL] [Abstract][Full Text] [Related]
7. Time-resolved single-cell analysis of Brca1 associated mammary tumourigenesis reveals aberrant differentiation of luminal progenitors.
Bach K; Pensa S; Zarocsinceva M; Kania K; Stockis J; Pinaud S; Lazarus KA; Shehata M; Simões BM; Greenhalgh AR; Howell SJ; Clarke RB; Caldas C; Halim TYF; Marioni JC; Khaled WT
Nat Commun; 2021 Mar; 12(1):1502. PubMed ID: 33686070
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of AKT suppresses the initiation and progression of
Baek HJ; Kim SE; Kim JK; Shin DH; Kim TH; Kim KG; Deng CX; Kim SS
Int J Biol Sci; 2018; 14(13):1769-1781. PubMed ID: 30443181
[TBL] [Abstract][Full Text] [Related]
9. Single-cell RNA-sequencing reveals distinct patterns of cell state heterogeneity in mouse models of breast cancer.
Yeo SK; Zhu X; Okamoto T; Hao M; Wang C; Lu P; Lu LJ; Guan JL
Elife; 2020 Aug; 9():. PubMed ID: 32840210
[TBL] [Abstract][Full Text] [Related]
10. Metastasis-Specific Gene Expression in Autochthonous and Allograft Mouse Mammary Tumor Models: Stratification and Identification of Targetable Signatures.
Ross C; Szczepanek K; Lee M; Yang H; Peer CJ; Kindrick J; Shankarappa P; Lin ZW; Sanford JD; Figg WD; Hunter KW
Mol Cancer Res; 2020 Sep; 18(9):1278-1289. PubMed ID: 32513899
[TBL] [Abstract][Full Text] [Related]
11. Transcriptional regulation of normal human mammary cell heterogeneity and its perturbation in breast cancer.
Pellacani D; Tan S; Lefort S; Eaves CJ
EMBO J; 2019 Jul; 38(14):e100330. PubMed ID: 31304632
[TBL] [Abstract][Full Text] [Related]
12. Genomic analyses as a guide to target identification and preclinical testing of mouse models of breast cancer.
Bennett CN; Green JE
Toxicol Pathol; 2010 Jan; 38(1):88-95. PubMed ID: 20080934
[TBL] [Abstract][Full Text] [Related]
13. Loss of function of GATA3 regulates FRA1 and c-FOS to activate EMT and promote mammary tumorigenesis and metastasis.
Liu X; Bai F; Wang Y; Wang C; Chan HL; Zheng C; Fang J; Zhu WG; Pei XH
Cell Death Dis; 2023 Jun; 14(6):370. PubMed ID: 37353480
[TBL] [Abstract][Full Text] [Related]
14. Research advances and new challenges in overcoming triple-negative breast cancer.
Zong Y; Pegram M
Cancer Drug Resist; 2021; 4(3):517-542. PubMed ID: 34888495
[TBL] [Abstract][Full Text] [Related]
15. PDGFRβ is an essential therapeutic target for BRCA1-deficient mammary tumors.
Bai F; Liu S; Liu X; Hollern DP; Scott A; Wang C; Zhang L; Fan C; Fu L; Perou CM; Zhu WG; Pei XH
Breast Cancer Res; 2021 Jan; 23(1):10. PubMed ID: 33478572
[TBL] [Abstract][Full Text] [Related]
16. Mouse Tumor Models for Advanced Cancer Immunotherapy.
Chulpanova DS; Kitaeva KV; Rutland CS; Rizvanov AA; Solovyeva VV
Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32526987
[TBL] [Abstract][Full Text] [Related]
17. MiR-29b-1-5p is altered in BRCA1 mutant tumours and is a biomarker in basal-like breast cancer.
Milevskiy MJG; Sandhu GK; Wronski A; Korbie D; Brewster BL; Shewan A; Edwards SL; French JD; Brown MA
Oncotarget; 2018 Sep; 9(71):33577-33588. PubMed ID: 30323900
[TBL] [Abstract][Full Text] [Related]
18. Mouse Models for Cancer Immunotherapy Research.
Olson B; Li Y; Lin Y; Liu ET; Patnaik A
Cancer Discov; 2018 Nov; 8(11):1358-1365. PubMed ID: 30309862
[TBL] [Abstract][Full Text] [Related]
19. Histological subtypes of mouse mammary tumors reveal conserved relationships to human cancers.
Hollern DP; Swiatnicki MR; Andrechek ER
PLoS Genet; 2018 Jan; 14(1):e1007135. PubMed ID: 29346386
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
